Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes

Stem Cell Reviews and Reports

Volumn 10, Issue 3, 2014, Pages 327-337

  Abdelalim, Essam M ^a,b   Bonnefond, Amélie ^a,c,d,e   Bennaceur Griscelli, Annelise ^f,g   Froguel, Philippe ^a,c,d,e,h  

^a HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^b Suez Canal University Faculty of Medicine   (Egypt)

^c INSTITUT PASTEUR DE LILLE   (France)

^d UNIV LILLE   (France)

^e France   (France)

^f Centre National de la Recherche Scientifique   (France)

^g BICÊTRE HOSPITAL   (France)

^h HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cell therapy; Diabetes mellitus; Embryonic stem cells (ESCs); Induced pluripotent stem cells (iPSCs); Insulin secreting cells; Pancreatic cells

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; CELL DIFFERENTIATION; DIABETES MELLITUS; EMBRYONIC STEM CELL; HUMAN; METABOLISM; PANCREAS ISLET BETA CELL; PERSONALIZED MEDICINE; PHYSIOLOGY; PLURIPOTENT STEM CELL; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; DIABETES MELLITUS; EMBRYONIC STEM CELLS; HUMANS; INDIVIDUALIZED MEDICINE; INDUCED PLURIPOTENT STEM CELLS; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL;

EID: 84899938324     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-014-9503-6     Document Type: Article

References (101)

1. Thomson, J. A., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145-1147.
2. Takahashi, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.
3. Aoi, T., et al. (2008). Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science, 321(5889), 699-702.
4. Hanna, J., et al. (2008). Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell, 133(2), 250-264.
5. Yu, J., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917-1920.
6. Abdelalim, E. M. (2013). Molecular mechanisms controlling the cell cycle in embryonic stem cells. Stem Cell Reviews, 9(6), 764-773.
7. Ruiz, S., et al. (2011). A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Current Biology, 21(1), 45-52.
8. Zhang, Z. N., et al. (2013). Oct4 maintains the pluripotency of human embryonic stem cells by inactivating p53 through Sirt1-mediated deacetylation. Stem Cells, 32, 157-65.
9. Chin, M. H., et al. (2009). Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell, 5(1), 111-123.
10. Stadtfeld, M., et al. (2008). Induced pluripotent stem cells generated without viral integration. Science, 322(5903), 945-949.
11. Danaei, G., et al. (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2. 7 million participants. Lancet, 378(9785), 31-40.
12. Gregg, E. W., et al. (2007). Mortality trends in men and women with diabetes, 1971 to 2000. Annals of Internal Medicine, 147(3), 149-155.
13. Tisch, R., & McDevitt, H. (1996). Insulin-dependent diabetes mellitus. Cell, 85(3), 291-297.
14. van Belle, T. L., Coppieters, K. T., & von Herrath, M. G. (2011). Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiological Reviews, 91(1), 79-118.
15. Doria, A., Patti, M. E., & Kahn, C. R. (2008). The emerging genetic architecture of type 2 diabetes. Cell Metabolism, 8(3), 186-200.
16. Bonnefond, A., Froguel, P., & Vaxillaire, M. (2010). The emerging genetics of type 2 diabetes. Trends in Molecular Medicine, 16(9), 407-416.
17. Vaxillaire, M., & Froguel, P. (2008). Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocrine Reviews, 29(3), 254-264.
18. Bonnefond, A., et al. (2012). Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One, 7(6), e37423.
19. Efrat, S. (2008). Beta-cell replacement for insulin-dependent diabetes mellitus. Advanced Drug Delivery Reviews, 60(2), 114-123.
20. Maehr, R., et al. (2009). Generation of pluripotent stem cells from patients with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 106(37), 15768-15773.
21. Tateishi, K., et al. (2008). Generation of insulin-secreting islet-like clusters from human skin fibroblasts. Journal of Biological Chemistry, 283(46), 31601-31607.
22. Zhang, D., et al. (2009). Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Research, 19(4), 429-438.
23. Jiang, J., et al. (2007). Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells, 25(8), 1940-1953.
24. Chen, S., et al. (2009). A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nature Chemical Biology, 5(4), 258-265.
25. Kroon, E., et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nature Biotechnology, 26(4), 443-452.
26. D'Amour, K. A., et al. (2006). Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nature Biotechnology, 24(11), 1392-1401.
27. Lumelsky, N., et al. (2001). Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science, 292(5520), 1389-1394.
28. Thatava, T., et al. (2011). Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene Therapy, 18(3), 283-293.
29. Kunisada, Y., et al. (2012). Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Research, 8(2), 274-284.
30. Nostro, M. C., et al. (2011). Stage-specific signaling through TGFbeta family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development, 138(5), 861-871.
31. Shim, J. H., et al. (2007). Directed differentiation of human embryonic stem cells towards a pancreatic cell fate. Diabetologia, 50(6), 1228-1238.
32. Gage, B. K., Webber, T. D., & Kieffer, T. J. (2013). Initial cell seeding density influences pancreatic endocrine development during in vitro differentiation of human embryonic stem cells. PLoS One, 8(12), e82076.
33. Jiang, W., et al. (2007). In vitro derivation of functional insulin-producing cells from human embryonic stem cells. Cell Research, 17(4), 333-344.
34. D'Amour, K. A., et al. (2005). Efficient differentiation of human embryonic stem cells to definitive endoderm. Nature Biotechnology, 23(12), 1534-1541.
35. Mfopou, J. K., et al. (2010). Noggin, retinoids, and fibroblast growth factor regulate hepatic or pancreatic fate of human embryonic stem cells. Gastroenterology, 138(7), 2233-2245. 2245 e1-14.
36. Johannesson, M., et al. (2009). FGF4 and retinoic acid direct differentiation of hESCs into PDX1-expressing foregut endoderm in a time- and concentration-dependent manner. PLoS One, 4(3), e4794.
37. McLean, A. B., et al. (2007). Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells, 25(1), 29-38.
38. Tian, T., & Meng, A. M. (2006). Nodal signals pattern vertebrate embryos. Cellular and Molecular Life Sciences, 63(6), 672-685.
39. Kubo, A., et al. (2004). Development of definitive endoderm from embryonic stem cells in culture. Development, 131(7), 1651-1662.
40. Hosoya, M. (2012). Preparation of pancreatic beta-cells from human iPS cells with small molecules. Islets, 4(3), 249-252.
41. Bruin, J. E., et al. (2013). Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells. Stem Cell Research, 12(1), 194-208.
42. Bone, H. K., et al. (2011). A novel chemically directed route for the generation of definitive endoderm from human embryonic stem cells based on inhibition of GSK-3. Journal of Cell Science, 124(Pt 12), 1992-2000.
43. Borowiak, M., et al. (2009). Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell, 4(4), 348-358.
44. Wandzioch, E., & Zaret, K. S. (2009). Dynamic signaling network for the specification of embryonic pancreas and liver progenitors. Science, 324(5935), 1707-1710.
45. Bernardo, A. S., et al. (2009). Biphasic induction of Pdx1 in mouse and human embryonic stem cells can mimic development of pancreatic beta-cells. Stem Cells, 27(2), 341-351.
46. Zhu, F. F., et al. (2011). Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells. Diabetologia, 54(9), 2325-2336.
47. Sakano, D., et al. (2014). VMAT2 identified as a regulator of late-stage beta-cell differentiation. Nat Chem Biol, 10, 141-8.
48. Ohmine, S., et al. (2012). Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency. Aging (Albany NY), 4(1), 60-73.
49. Rezania, A., et al. (2013). Enrichment of human embryonic stem cell-derived NKX6. 1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem Cells, 31, 2432-2442.
50. Blyszczuk, P., et al. (2003). Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proceedings of the National Academy of Sciences of the United States of America, 100(3), 998-1003.
51. Kwon, Y. D., et al. (2005). Cellular manipulation of human embryonic stem cells by TAT-PDX1 protein transduction. Molecular Therapy, 12(1), 28-32.
52. Soria, B., et al. (2000). Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes, 49(2), 157-162.
53. Liew, C. G., et al. (2008). PAX4 enhances beta-cell differentiation of human embryonic stem cells. PLoS One, 3(3), e1783.
54. Hua, H., et al. (2013). iPSC-derived beta cells model diabetes due to glucokinase deficiency. Journal of Clinical Investigation, 123(7), 3146-3153.
55. Thatava, T., et al. (2013). Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Molecular Therapy, 21(1), 228-239.
56. Teo, A. K., Wagers, A. J., & Kulkarni, R. N. (2013). New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism. Cell Metabolism, 18(6), 775-791.
57. Kelly, O. G., et al. (2011). Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells. Nature Biotechnology, 29(8), 750-756.
58. Cai, J., et al. (2010). Generation of homogeneous PDX1(+) pancreatic progenitors from human ES cell-derived endoderm cells. Journal of Molecular Cell Biology, 2(1), 50-60.
59. Xu, X., Browning, V. L., & Odorico, J. S. (2011). Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells. Mechanisms of Development, 128(7-10), 412-427.
60. Rezania, A., et al. (2012). Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes, 61(8), 2016-2029.
61. Bruin, J. E., et al. (2013). Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia, 56(9), 1987-1998.
62. Alipio, Z., et al. (2010). Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proceedings of the National Academy of Sciences of the United States of America, 107(30), 13426-13431.
63. Jeon, K., et al. (2012). Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells and Development, 21(14), 2642-2655.
64. Yang, X., et al. (2007). Nuclear reprogramming of cloned embryos and its implications for therapeutic cloning. Nature Genetics, 39(3), 295-302.
65. Lanza, R. P., Cibelli, J. B., & West, M. D. (1999). Prospects for the use of nuclear transfer in human transplantation. Nature Biotechnology, 17(12), 1171-1174.
66. Wilmut, I., et al. (1997). Viable offspring derived from fetal and adult mammalian cells. Nature, 385(6619), 810-813.
67. Tachibana, M., et al. (2013). Human embryonic stem cells derived by somatic cell nuclear transfer. Cell, 153(6), 1228-1238.
68. Araki, R., et al. (2013). Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 494(7435), 100-104.
69. Sermon, K. D., et al. (2009). Creation of a registry for human embryonic stem cells carrying an inherited defect: joint collaboration between ESHRE and hESCreg. Human Reproduction, 24(7), 1556-1560.
70. Verlinsky, Y., et al. (2005). Human embryonic stem cell lines with genetic disorders. Reproductive Biomedicine Online, 10(1), 105-110.
71. Eiges, R., et al. (2007). Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell, 1(5), 568-577.
72. Mateizel, I., et al. (2006). Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Human Reproduction, 21(2), 503-511.
73. Lee, G., & Studer, L. (2010). Induced pluripotent stem cell technology for the study of human disease. Nature Methods, 7(1), 25-27.
74. Maehr, R. (2011). iPS cells in type 1 diabetes research and treatment. Clinical Pharmacology and Therapeutics, 89(5), 750-753.
75. Teo, A. K., et al. (2013). Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. Journal of Biological Chemistry, 288(8), 5353-5356.
76. Kudva, Y. C., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Translational Medicine, 1(6), 451-461.
77. Velho, G., et al. (1992). Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet, 340(8817), 444-448.
78. Estalella, I., et al. (2007). Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clinical Endocrinology, 67(4), 538-546.
79. Froguel, P., et al. (1993). Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. New England Journal of Medicine, 328(10), 697-702.
80. Byrne, M. M., et al. (1994). Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. Journal of Clinical Investigation, 93(3), 1120-1130.
81. Li, H., et al. (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature, 460(7259), 1136-1139.
82. Banito, A., et al. (2009). Senescence impairs successful reprogramming to pluripotent stem cells. Genes and Development, 23(18), 2134-2139.
83. Hanna, J., et al. (2009). Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell, 4(6), 513-524.
84. Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313-317.
85. Okita, K., et al. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322(5903), 949-953.
86. Soldner, F., et al. (2009). Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 136(5), 964-977.
87. Kaji, K., et al. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature, 458(7239), 771-775.
88. Woltjen, K., et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 458(7239), 766-770.
89. Zhou, H., et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 4(5), 381-384.
90. Kim, D., et al. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 4(6), 472-476.
91. Yamanaka, S. (2007). Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell, 1(1), 39-49.
92. Knoepfler, P. S. (2008). Why myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell, 2(1), 18-21.
93. Nakagawa, M., et al. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotechnology, 26(1), 101-106.
94. Wernig, M., et al. (2008). c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell, 2(1), 10-12.
95. Obokata, H., et al. (2014). Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature, 505(7485), 641-647.
96. Obokata, H., et al. (2014). Bidirectional developmental potential in reprogrammed cells with acquired pluripotency. Nature, 505(7485), 676-680.
97. Santana, A., et al. (2006). Insulin-producing cells derived from stem cells: recent progress and future directions. Journal of Cellular and Molecular Medicine, 10(4), 866-883.
98. Shapiro, A. M., et al. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine, 343(4), 230-238.
99. Penfornis, A., & Kury-Paulin, S. (2006). Immunosuppressive drug-induced diabetes. Diabetes & Metabolism, 32(5 Pt 2), 539-546.
100. Fiorina, P., Voltarelli, J., & Zavazava, N. (2011). Immunological applications of stem cells in type 1 diabetes. Endocrine Reviews, 32(6), 725-754.
101. Patterson, M., et al. (2012). Defining the nature of human pluripotent stem cell progeny. Cell Research, 22(1), 178-193.